Ranopto (ranibizumab)

pCPA File Number: 22329
Negotiation Status:
Concluded with an LOI
Indication(s):
For the treatment of:
• neovascular (wet) age-related macular degeneration (AMD)
• visual impairment due to diabetic macular edema (DME)
• visual impairment due to macular edema secondary to retinal vein occlusion (RVO)
• visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM)
• visual impairment due to choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy
Sponsor/Manufacturer:
Teva Canada
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: